顶部联系方式
EVENTS
LEAST NEWS

2023-02-21

2020-09-22
In the last 3 bidding processing, Chongqing Huapont pharm Co., Ltd.’s products: Moxifloxacin tablet, Anastrozole tablet and Levocetirizine HCL tablet were successful won in the centralised procurement process.
Centralised Procurement History:
1st Round: start from 2019 December 15th, total of 25 medicines were open for bidding, covering 11 provinces and regions;
2nd Round: start from 2020 January 17th, total of 33 medicines were open for bidding, covering 23 provinces and regions;
3rd Round: start from 2020 August 20th, total of 56 medicines were open for bidding, covering 25 provinces and regions;
In the last 3 bidding processing, Chongqing Huapont pharm Co., Ltd.’s products: Moxifloxacin tablet, Anastrozole tablet and Levocetirizine HCL tablet were successful won in the centralised procurement process.
Centralised Procurement History:
1st Round: start from 2019 December 15th, total of 25 medicines were open for bidding, covering 11 provinces and regions;
2nd Round: start from 2020 January 17th, total of 33 medicines were open for bidding, covering 23 provinces and regions;
3rd Round: start from 2020 August 20th, total of 56 medicines were open for bidding, covering 25 provinces and regions;

2020-06-29
A few clinically approved drugs, such as remdesivir, chloroquine, hydroxychloroquine, nafamostat, camostat, and ivermectin, exhibited anti-SARS-CoV-2 activity in vitro and/or in a small number of patients. However, their clinical use may be limited by anti-SARS-CoV-2 50 % maximal effective concentrations (EC50) that exceeded their achievable peak serum concentrations (Cmax), side effects, and/or availability. To find more immediately available COVID-19 antivirals. The Author established a two-tier drug screening system that combines SARS-CoV-2 enzyme-linked immunosorbent assay and cell viability assay, and applied it to screen a library consisting 1528 FDA-approved drugs. Cetilistat (anti-pancreatic lipase), diiodohydroxyquinoline (anti-parasitic), abirateroneacetate (synthetic androstane steroid), and bexarotene (antineoplastic retinoid) exhibited potent in vitro anti-SARS-CoV-2 activity (EC501.13–2.01μM). Bexarotene demonstrated the highest Cmax: EC50 ratio (1.69) which was higher than those of chloroquine, hydroxychloroquine.
Article:Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system
A few clinically approved drugs, such as remdesivir, chloroquine, hydroxychloroquine, nafamostat, camostat, and ivermectin, exhibited anti-SARS-CoV-2 activity in vitro and/or in a small number of patients. However, their clinical use may be limited by anti-SARS-CoV-2 50 % maximal effective concentrations (EC50) that exceeded their achievable peak serum concentrations (Cmax), side effects, and/or availability. To find more immediately available COVID-19 antivirals. The Author established a two-tier drug screening system that combines SARS-CoV-2 enzyme-linked immunosorbent assay and cell viability assay, and applied it to screen a library consisting 1528 FDA-approved drugs. Cetilistat (anti-pancreatic lipase), diiodohydroxyquinoline (anti-parasitic), abirateroneacetate (synthetic androstane steroid), and bexarotene (antineoplastic retinoid) exhibited potent in vitro anti-SARS-CoV-2 activity (EC501.13–2.01μM). Bexarotene demonstrated the highest Cmax: EC50 ratio (1.69) which was higher than those of chloroquine, hydroxychloroquine.
Article:Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system

2020-06-22
In China, Novartis also apply Ruxolitinib clinical study to treat COVID-19.
Chongqing Huapont Pharmaceutical Co., Ltd. started to develop Ruxolitinib since 2014, submitted DMF#29480 to USFDA and paid GUDFA fee in 2015. In order to fight against COVID-19 and protect human beings health, Huapont commit to do our best for keeping effective supply Ruxolitinib API.
In China, Novartis also apply Ruxolitinib clinical study to treat COVID-19.
Chongqing Huapont Pharmaceutical Co., Ltd. started to develop Ruxolitinib since 2014, submitted DMF#29480 to USFDA and paid GUDFA fee in 2015. In order to fight against COVID-19 and protect human beings health, Huapont commit to do our best for keeping effective supply Ruxolitinib API.
PRODUCTS

.GMP: available
.Written Confirmation: available
.CAS No: 55079-83-9
.Chemical Formula: C21H26O3
.Molecular Weight: 326.4
.Specification: the current Ph.Eur., USP, Ch.P
.DMF Open Part: available upon request
.MSDS: available upon request
.Therapeutic class: anti psoriasis



.GMP: available
.Written Confirmation: available
.CAS No: 55079-83-9
.Chemical Formula: C21H26O3
.Molecular Weight: 326.4
.Specification: the current Ph.Eur., USP, Ch.P
.DMF Open Part: available upon request
.MSDS: available upon request
.Therapeutic class: anti psoriasis
FOCUS ON
FOCUS ON
Huapont Pharm has been focusing on retinoids since start-up of its business, and are proud of a lot of experts with rich developing and manufacturing experiences.
We manufacturing APIs including:
● First generation:
Tretinoin(Retinoic acid), Isotretinoin and Alitretinoin
● Second generation:
Etretinate,Acitretin
● Third generation:
Adapalene, Bexarotene and Tazarotene
We also manufacture Tretinoin cream, Isotretinoin soft capsules, Acitretin capsules, Adapalene cream and Tazarotene cream/gel.
NEW PLANT
NEW PLANT
A now finished product plant of Huapont Pharm will be put in use in 2018, covering an area about 113516 m2 and total construction area more than 180000 m2. The new plant is designed to comply with EU GMP with a total investment of billion RMB
With a 5-times capacity increment by comparing the current plant, the new plant has 7 production lines which can manufacture:
● 25 million units for external preparations,
● 35 million units for external preparations(hormones),
● 2 billion units for tablets.
● 0.6 billion units for hard capsules,
● 7.2 million units for small volume injections
● 50 million units for oral solution
● 25 million units for soft capsules.

QUICK LINKS
Quick Links
Chongqing Guide: http://www.chongqing-guide.com
MEP: http://english.mep.gov.cn
CONTACT INFO
Contact Info
TEL: +86-23-67886927
TEL: +86-23-67886928
EMAIL: api@huapont.cn
ADD.: No.69 Xingguang Avenue, Renhe Town, Yubei District,Chongqing, China 401121
FEEDBACK
地址版权
© 2020 Chongqing Huapont Pharmaceutical Co., Ltd. All Rights Reserved. Powered by: www.300.cn 渝ICP备05003324号
手机版地址版权
© 2020 Chongqing Huapont Pharmaceutical Co., Ltd.